Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.84 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618413 | 0.91 | CHEK1 (1.00) | CHEK1CHEK2KCNH2 | |
| SCHEMBL620332 | 0.87 | CHEK1 (0.74) | CHEK1CHEK2KCNH2 | |
| SCHEMBL619445 | 0.83 | CHEK1 (0.68) | CHEK1CHEK2 | |
| SCHEMBL10172521 | 0.79 | CHEK1 (0.82) | CHEK1CHEK2KCNH2 | |
| SCHEMBL618154 | 0.77 | CHEK1 (0.57) | CHEK1CHEK2KCNH2 | |
| SCHEMBL13893664 | 0.77 | CHEK1 (0.76) | CHEK1CHEK2KCNH2 | |
| SCHEMBL10172449 | 0.76 | CHEK1 (0.66) | CHEK1CHEK2 | |
| SCHEMBL10218146 | 0.73 | CHEK1 (0.55) | CHEK1CHEK2KCNH2 | |
| SCHEMBL10172537 | 0.73 | CHEK1 (0.63) | CHEK1CHEK2 | |
| SCHEMBL10172547 | 0.72 | CHEK1 (0.83) | CHEK1CHEK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.